Quick Answer
KYNTRA BIO, INC. reported Operating Income Loss of -$45.90 million for the year ending 2025.
- KYNTRA BIO, INC. showed an increase of +69.5% in Operating Income Loss from 2024 to 2025.
- This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$14.21 million | Q2 2014: $49.17 million | Q3 2014: -$37.10 million | Q1 2015: -$44.72 million | Q2 2015: $59.32 million | Q3 2015: -$43.77 million | Q1 2016: -$26.79 million | Q2 2016: $26.51 million | Q3 2016: -$22.10 million | Q1 2017: -$28.82 million | Q2 2017: -$30.14 million | Q3 2017: -$22.74 million | Q1 2018: -$40.60 million | Q2 2018: -$23.24 million | Q3 2018: -$42.77 million | Q1 2019: -$48.84 million | Q2 2019: $112.82 million | Q3 2019: -$52.85 million | Q1 2020: -$81.07 million | Q2 2020: -$85.14 million | Q3 2020: $32.33 million | Q1 2021: -$70.43 million | Q2 2021: -$133.84 million | Q3 2021: $50.97 million | Q1 2022: -$62.99 million | Q2 2022: -$78.22 million | Q3 2022: -$93.66 million | Q1 2023: -$76.09 million | Q2 2023: -$88.05 million | Q3 2023: -$63.48 million | Q1 2024: -$49.18 million | Q2 2024: -$46.41 million | Q3 2024: -$47.69 million | Q1 2025: -$14.92 million | Q2 2025: -$12.05 million | Q3 2025: -$5.41 million.
- Over the full 13 years of available data (2013 to 2025), KYNTRA BIO, INC.'s Operating Income Loss has declined by 477.4%.
- Historical annual values: Fiscal year 2025: -$45.90 million | Fiscal year 2024: -$150.42 million | Fiscal year 2023: -$322.72 million | Fiscal year 2022: -$301.03 million | Fiscal year 2021: -$288.53 million | Fiscal year 2020: -$191.88 million | Fiscal year 2019: -$89.31 million | Fiscal year 2018: -$86.69 million | Fiscal year 2017: -$117.28 million | Fiscal year 2016: -$50.04 million | Fiscal year 2015: -$77.63 million | Fiscal year 2014: -$50.10 million | Fiscal year 2013: -$7.95 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: